edivoxetine (LY2216684) / Eli Lilly - LARVOL DELTA

Side effect profile and comparative tolerability of newer generation antidepressants in the acute treatment of major depressive disorder in children and adolescents: protocol for a systematic review and network meta-analysis. (PubMed, BMJ Open) - "The following antidepressants will be considered: agomelatine, alaproclate, bupropion, citalopram, desvenlafaxine, duloxetine, edivoxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, milnacipran, mirtazapine, paroxetine, reboxetine, sertraline, venlafaxine, vilazodone and vortioxetine. The findings will be published in a peer-reviewed journal and may be presented at international conferences. CRD420251011399."

Adverse events • Journal • Retrospective data • CNS Disorders • Depression • Major Depressive Disorder • Mental Retardation • Mood Disorders • Psychiatry • Suicidal Ideation

Efficacy and safety of monoamine reuptake inhibitors in attention deficit hyperactivity disorder: A Bayesian network meta-analysis. (PubMed, J Psychiatr Res) - "The drugs showing significant reduction on the ADHD rating scale as compared to placebo are bupropion (SMD: 0.33; 95%CrI: 0.60,-0.059), dasotraline(SMD: 0.49; 95%CrI: 0.82,-0.16), venlafaxine(SMD: 0.71; 95%CrI: 1.3,-0.15), viloxazine(SMD: 0.45; 95%CrI: 0.77,-0.12). Other drugs (centanafadine, duloxetine, edivoxetine, reboxetine, tipepidine, vortioxetine) were no better than placebo in reducing symptom severity of ADHD...Among all, duloxetine (OR:15; 95%CrI:1.8130) showed significantly more treatment-emergent adverse events than methylphenidate. In conclusion, venlafaxine, viloxazine, and bupropion are the most efficacious MRIs for ADHD symptom reduction as compared to placebo with high certainty of evidence."

Journal • Retrospective data • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

The role of adrenergic neurotransmitter reuptake inhibitors in the ADHD armamentarium. (PubMed, Expert Opin Pharmacother) - "The authors conducted a PubMed literature search using the following key words: 'ADHD' AND 'adrenergic reuptake inhibitors' OR 'nonstimulants' OR 'atomoxetine' OR 'Viloxazine' OR 'Dasotraline' OR 'Centanafadine' OR 'PDC-1421' OR 'Reboxetine' OR 'Edivoxetine' OR 'Bupropion' OR 'Venlafaxine' OR 'Duloxetine.' They reviewed FDA fact sheets of available medications for safety/tolerability studies and reviewed published clinical studies of these medications for treatment of ADHD. Adrenergic neurotransmitter reuptake inhibitors fit the diverse needs of children and adolescents with ADHD with 1) poor tolerability to stimulants (e.g. due to growth suppression, insomnia, rebound irritability, co-morbid depression, anxiety and tic disorders, substance abuse or diversion concerns), 2) cardiac risks, and/or 3) need for extended duration of action. Their differences in receptor..."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Depression • Insomnia • Mood Disorders • Psychiatry • Sleep Disorder • Substance Abuse • Tic Disorders • Tourette Syndrome

ADHD-A Clinician's Bird's Eye View of Current Status and New Vistas! (PubMed, Psychopharmacol Bull) - "Drugs for ADHD in the pipeline include-dasotraline, armodafinil, tipepidine, edivoxetine, metadoxine, and memantine. Literature on ADHD keeps expanding towards advancing our understanding of the complex and heterogeneous intricacies of this commonplace neurodevelopmental disorder and hence informing better decisions on how best to manage its diverse cognitive, behavioural, social and medical facets."

Journal • Review • ADHD (Impulsive Aggression) • Allergy • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Epilepsy • Genetic Disorders • Immunology • Mood Disorders • Movement Disorders • Obesity • Psychiatry • Sleep Disorder

Effects of discontinuation of drugs used for augmentation on treatment outcomes in depression: a systematic review and meta-analysis (ECNP 2019) - "For augmentation, risperidone (two studies), lithium (two studies), olanzapine (one study), and edivoxetine (one study) were used. The currently available evidence suggests that “add-on” drug used for augmentation therapy for depression may need to be continued. The fact that there has been only a small number of studies on this topic clearly warrants further investigations."

Retrospective data • Review

Comparative Efficacy of Antidepressants on Measures of Functional Outcomes by Sheehan Disability Scale (SDS) in Patients with Major Depressive Disorder (WPA 2019) - "Forty-two studies including 22,113 subjects that evaluated the effects of 16 different antidepressants on SDS functional outcomes were finally included in the analysis. The results of 39 pairwise comparisons indicated that function outcomes were significantly improved in subjects treated with antidepressants compared to placebo (SMD = -0.22, 95% CI: -0.292, -0.147, p<0.001). The network meta-analysis showed the rank of 16 antidepressants’ efficacy of functional outcomes are as follows: lurasidone, risperidone, duloxetine, paroxetine, levomilnacipran, edivoxetine, venlafaxine, desvenlafaxine, quetiapine, escitalopram, bupropion, sertraline, vortioxetine, agomelatine, fluoxetine, placebo, and AZD6765."

Clinical